There are many factors affecting the effectiveness of antiviral treatment for hepatitis B, and whether the treatment is standardized is also an important reason. Therefore: First, the timing of treatment should be standardized Not all people infected with hepatitis B virus need immediate antiviral treatment. Chronic hepatitis activity, recent serum aminotransferase (ALT) is higher than the upper limit of normal more than two times, is the best time to implement hepatitis B antiviral treatment, this part of the patient, if no special reasons, should receive antiviral treatment in time. For those patients whose liver function tests are normal for many times, individualized treatment plan should be implemented according to different situations. In general, since the effect of antiviral treatment is relatively poor at this time, antiviral drugs can be temporarily not used for regular follow-up, but if the patients have a history of hepatitis B attacks in the past, or still have signs and symptoms related to liver disease or other laboratory tests, imaging abnormalities, especially those who are older than 40 years old and have a family history of hepatitis B and its related diseases, it is the best time to implement antiviral treatment. However, if the patient has a history of hepatitis B attack, or still has symptoms and signs related to liver disease or other laboratory or imaging abnormalities, especially if the patient is older than 40 years old, or has a family history of hepatitis B and its related diseases, he/she should undergo further examination, such as liver fibrosis index, liver elasticity (hardness) measurement, and liver biopsy if necessary. As for patients with cirrhosis after hepatitis B, the antiviral treatment “threshold” should be lowered: as long as there is evidence of hepatitis B virus replication, regardless of whether the liver function transaminases are elevated or not, antiviral treatment should be carried out. Second, the choice of drugs should be standardized At present, domestic and foreign recognized anti-hepatitis B virus drugs have two types: one type of interferon, including ordinary interferon and polyethylene glycol interferon (commonly known as “long-acting interferon”), and the other type of nucleoside (acid) analogues, the domestic existing lamivudine, adefovir, entecavir and tibivudine, which are the two types of six kinds of drugs. These six drugs have their own strengths and weaknesses in terms of antiviral strength, inhibition of viral replication, safety, incidence of drug resistance, and price, etc. They should be selected reasonably according to the patient’s condition, duration of infection, presence or absence of co-morbidities, age or even gender, and ability to receive treatment (including economic conditions). For example, if the patient’s age is young, treatment compliance is good, and viral load is low, interferon therapy is often used to achieve better results, on the contrary, patients with cirrhosis after hepatitis B should not or can not use interferon, and nucleoside analogs that have strong effects and a lower incidence of drug resistance in long-term application should be used, or two nucleoside analogs should be used in combination.